NASDAQ:SCNI Scinai Immunotherapeutics (SCNI) Stock Price, News & Analysis $1.54 +0.01 (+0.65%) Closing price 04:00 PM EasternExtended Trading$1.55 +0.01 (+0.65%) As of 07:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisChartCompetitorsEarningsFDA EventsHeadlinesSEC FilingsShort InterestTrendsBuy This Stock About Scinai Immunotherapeutics Stock (NASDAQ:SCNI) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get SCNI alerts:Sign Up Key Stats Today's Range$1.47▼$1.5750-Day Range$1.43▼$2.5252-Week Range$1.40▼$6.18Volume116,615 shsAverage Volume549,378 shsMarket Capitalization$1.54 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Scinai Immunotherapeutics Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious and autoimmune diseases in Israel. It has licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications. The company was formerly known as BiondVax Pharmaceuticals Ltd. and changed its name to Scinai Immunotherapeutics Ltd. in September 2023. Scinai Immunotherapeutics Ltd. was incorporated in 2003 and is headquartered in Jerusalem, Israel. Read More Scinai Immunotherapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks18th Percentile Overall ScoreSCNI MarketRank™: Scinai Immunotherapeutics scored higher than 18% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for Scinai Immunotherapeutics. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Scinai Immunotherapeutics is -0.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Scinai Immunotherapeutics is -0.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioScinai Immunotherapeutics has a P/B Ratio of 0.30. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted23.08% of the outstanding shares of Scinai Immunotherapeutics have been sold short.Short Interest Ratio / Days to CoverScinai Immunotherapeutics has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Scinai Immunotherapeutics has recently decreased by 16.19%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldScinai Immunotherapeutics does not currently pay a dividend.Dividend GrowthScinai Immunotherapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted23.08% of the outstanding shares of Scinai Immunotherapeutics have been sold short.Short Interest Ratio / Days to CoverScinai Immunotherapeutics has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Scinai Immunotherapeutics has recently decreased by 16.19%, indicating that investor sentiment is improving significantly. News and Social Media2.2 / 5News Sentiment0.93 News SentimentScinai Immunotherapeutics has a news sentiment score of 0.93. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 1.12 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Scinai Immunotherapeutics this week, compared to 0 articles on an average week.Search InterestOnly 1 people have searched for SCNI on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Scinai Immunotherapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 6.03% of the stock of Scinai Immunotherapeutics is held by insiders.Percentage Held by Institutions58.41% of the stock of Scinai Immunotherapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Scinai Immunotherapeutics' insider trading history. Receive SCNI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Scinai Immunotherapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. SCNI Stock News HeadlinesScinai Reports Six-Month 2025 Financial Results Highlighting Continued CDMO Revenue Growth and Strengthened Balance SheetSeptember 2 at 7:30 AM | prnewswire.comScinai Immunotherapeutics (NASDAQ:SCNI) Stock Rating Upgraded by Wall Street ZenAugust 30 at 3:17 AM | americanbankingnews.comLeaked Gov’t Memo Reveals $100 Trillion DeadlineOnly Days Left to Claim Your Share of Trump's $100T Play Trump's economic blueprint is about to go live, and the deadline is fast-approaching. A new federal plan could legally unlock $100 trillion in U.S. resources... and one $10 stock could lead the charge. Former hedge fund manager Whitney Tilson explains how to act now, before this hits the headlines.September 2 at 2:00 AM | Stansberry Research (Ad)Scinai Announces New Peer-Reviewed Publication Supporting PC111 as a Disease-Modifying Therapy for Pemphigus and SJS/TENJuly 29, 2025 | prnewswire.comScinai Highlights New Funding and CDMO Growth Ahead of BIO International Convention 2025June 12, 2025 | prnewswire.comScinai Immunotherapeutics Receives Italian Government Clearance Under Golden Power Regulation for Potential Acquisition of Pincell S.r.l.June 5, 2025 | prnewswire.comScinai Immunotherapeutics Ltd.: Scinai Reports Q1 2025 Financial Results Highlighting Strong CDMO Revenue Momentum and Reduced Cash BurnMay 30, 2025 | finanznachrichten.deScinai Reports Q1 2025 Financial Results Highlighting Strong CDMO Revenue Momentum and Reduced Cash BurnMay 30, 2025 | prnewswire.comSee More Headlines SCNI Stock Analysis - Frequently Asked Questions How have SCNI shares performed this year? Scinai Immunotherapeutics' stock was trading at $3.35 at the start of the year. Since then, SCNI stock has decreased by 54.0% and is now trading at $1.54. How were Scinai Immunotherapeutics' earnings last quarter? Scinai Immunotherapeutics Ltd. Sponsored ADR (NASDAQ:SCNI) issued its quarterly earnings results on Wednesday, May, 7th. The company reported ($10.40) earnings per share for the quarter. The company earned $0.21 million during the quarter. When did Scinai Immunotherapeutics' stock split? Scinai Immunotherapeutics shares reverse split before market open on Tuesday, May 21st 2024.The 1-10 reverse split was announced on Tuesday, May 21st 2024. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, May 21st 2024. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. How do I buy shares of Scinai Immunotherapeutics? Shares of SCNI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Scinai Immunotherapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Scinai Immunotherapeutics investors own include NVIDIA (NVDA), Broadcom (AVGO), Adobe (ADBE), Arista Networks (ANET), AppLovin (APP), e.l.f. Beauty (ELF) and Disc Medicine (IRON). Company Calendar Last Earnings5/07/2025Today9/02/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:SCNI Previous SymbolNASDAQ:SCNI CIK1611747 Webwww.scinai.com Phone972-8-930-2529Fax972-8930-2531Employees20Year FoundedN/AProfitability EPS (Trailing Twelve Months)($9.57) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$4.80 million Net MarginsN/A Pretax Margin728.88% Return on EquityN/A Return on Assets-40.60% Debt Debt-to-Equity Ratio0.06 Current Ratio1.32 Quick Ratio1.32 Sales & Book Value Annual Sales$660 thousand Price / Sales2.33 Cash FlowN/A Price / Cash FlowN/A Book Value$5.10 per share Price / Book0.30Miscellaneous Outstanding Shares1,000,000Free Float940,000Market Cap$1.54 million OptionableNot Optionable Beta1.83 These 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (NASDAQ:SCNI) was last updated on 9/2/2025 by MarketBeat.com Staff From Our PartnersMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredOne tiny company just cracked Google’s $19B problemGoogle’s AI-powered search could cost $20 billion a year in electricity—nearly half its profits. But new resea...True Market Insiders | SponsoredThe day and month stocks are most likely to crash nextGood News for Stocks 50-year Wall Street veteran, Marc Chaikin is stepping forward to share why history giv...Chaikin Analytics | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | Sponsored2013 Bitcoin miner reveals his trading system (free)While everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredI’d rather trade news like this than gamble on hypeReal traders are watching Nvidia’s next move—after U.S. approval to resume chip sales to China. This reversal ...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Scinai Immunotherapeutics Ltd. Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Scinai Immunotherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free SCNI Stock Alerts